Efficacy and Safety of Adding Clopidogrel to Aspirin or Use of Metoprolol in Myocardial Infarction
Status:
Completed
Trial end date:
2005-02-01
Target enrollment:
Participant gender:
Summary
COMMIT/CCS2 is a large randomised trial of the effects of clopidogrel plus Aspirin versus
Aspirin alone in acute heart disease. Patients presenting within 24 hours of the onset of
suspected acute MI were potentially eligible provided they were thought to have ST elevation
or other ischaemic ECG abnormality with no clear indication for, or contraindication to,
trial treatment. All patients were to be given 162 mg ASA daily and, in addition, 75 mg
clopidogrel daily or matching placebo for 4 weeks or until prior discharge or death.
(Patients were also randomised separately in a 2 X 2 factorial design between metoprolol
versus placebo.) The two main study endpoints are death and the composite outcome of death,
non-fatal reinfarction or stroke during the scheduled treatment period in hospital.